Reversing Immune Aging to Improve Immunotherapy Outcomes.
Abstract
Age-related immune decline may limit cancer immunotherapy effectiveness, particularly in patients ages 75 and older. Researchers are exploring mRNA-based immune rejuvenation and senolytics as potential solutions, with a growing number of human trials now testing whether targeting immune aging can improve treatment response. Translating these findings more broadly will require addressing safety concerns and the complexity of human immune aging.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper claims that reversing immune aging can improve the effectiveness of cancer immunotherapy in older patients. This research addresses the root causes of immune decline associated with aging, which is a significant aspect of longevity research.
Author of this paper? Send a correction.